December 15th, 2015 – Leiden, The Netherlands
OcellO today announced continuation of the collaboration in discovery projects with Synthon Biopharmaceuticals whereby OcellO will provide services for high-content screening in patient-derived in vitro tissue models. OcellO will use panels of patient-derived 3D tumour models for testing of Synthon’s antibody-drug conjugates for its preclinical oncology research programs.
Patient-derived 3D tumour cultures bridge the gap between conventional cell line derived in vitro models and in vivo models. Furthermore, OcellO’s image-based analysis of 3D tissues provides more detailed insight into the effects of ADCs on tumour tissues compared to conventional growth and killing assays.
“The collaboration with Synthon builds on an earlier successful project and is an important recognition of the added value of our screening technology for the pre-clinical evaluation of drug performance. This is a great opportunity to apply our human tissue models to the development of state-of-the-art therapeutic molecules for the improvement of cancer treatment”, said Leo Price, CEO of OcellO.
Marco Timmers, CSO of Synthon, commented: “We are very excited about our partnership with OcellO. It allows Synthon to benefit from OcellO’s leading position in tissue based screening, which we expect will be beneficial for a number of projects in our pipeline”.
OcellO is a CRO that offers drug screening and profiling services using 3D cell culture models of cancers and other diseases. OcellO uses high-content 3D imaging and analysis to measure drug effects, extracting clinically relevant information on compound effects. For more information, contact Leo Price ([email protected]) or visit the website (www.OcellO.nl).